4.95 USD
▼-0.04-0.80%
盘后 6.11 0.00%
2026-09-16
市值
$31.54M
市盈率
—
EPS
-7.31
股息率
—
52 周区间
3.98 – 13.69
成交量
28.11K
Beta
2.33
目标价
53.43
52W 低 3.9852W 高 13.69
价格走势
公司简介
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protea...